Amicus Therapeutics (NASDAQ:FOLD) Given New $15.00 Price Target at Bank of America

Amicus Therapeutics (NASDAQ:FOLD) had its price target lifted by Bank of America from $13.00 to $15.00 in a research note published on Thursday, Benzinga reports. The firm currently has a buy rating on the biopharmaceutical company’s stock.

Other research analysts have also recently issued reports about the company. Cantor Fitzgerald restated an “overweight” rating and set a $20.00 price target on shares of Amicus Therapeutics in a research note on Friday, September 20th. Morgan Stanley reduced their price objective on Amicus Therapeutics from $19.00 to $18.00 and set an “overweight” rating on the stock in a research note on Friday, October 11th. StockNews.com cut Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, October 15th. JPMorgan Chase & Co. reduced their price objective on Amicus Therapeutics from $17.00 to $16.00 and set an “overweight” rating on the stock in a research note on Friday, August 16th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Amicus Therapeutics in a research note on Friday, August 9th. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, Amicus Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $17.13.

Amicus Therapeutics Trading Down 0.6 %

Shares of Amicus Therapeutics stock opened at $11.90 on Thursday. The firm has a market capitalization of $3.52 billion, a price-to-earnings ratio of -24.29 and a beta of 0.69. Amicus Therapeutics has a fifty-two week low of $9.02 and a fifty-two week high of $14.57. The company has a debt-to-equity ratio of 2.93, a quick ratio of 2.26 and a current ratio of 2.75. The stock has a 50 day moving average of $11.17 and a 200 day moving average of $10.56.

Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.05) EPS for the quarter, hitting analysts’ consensus estimates of ($0.05). Amicus Therapeutics had a negative return on equity of 41.47% and a negative net margin of 26.23%. The company had revenue of $126.67 million for the quarter, compared to analysts’ expectations of $121.21 million. During the same period in the prior year, the firm earned ($0.15) earnings per share. The firm’s revenue was up 34.0% compared to the same quarter last year. As a group, research analysts predict that Amicus Therapeutics will post -0.07 earnings per share for the current year.

Insider Buying and Selling at Amicus Therapeutics

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,500 shares of the firm’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $11.71, for a total value of $87,825.00. Following the sale, the chief executive officer now directly owns 886,654 shares in the company, valued at $10,382,718.34. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold a total of 22,500 shares of company stock worth $244,875 over the last ninety days. Corporate insiders own 2.20% of the company’s stock.

Hedge Funds Weigh In On Amicus Therapeutics

Hedge funds have recently made changes to their positions in the company. Blue Trust Inc. grew its holdings in shares of Amicus Therapeutics by 1,705.4% during the third quarter. Blue Trust Inc. now owns 2,997 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 2,831 shares during the last quarter. Headlands Technologies LLC purchased a new position in shares of Amicus Therapeutics during the second quarter worth about $89,000. Sage Capital Advisors llc purchased a new position in shares of Amicus Therapeutics during the second quarter worth about $103,000. EntryPoint Capital LLC grew its holdings in shares of Amicus Therapeutics by 278.8% during the first quarter. EntryPoint Capital LLC now owns 13,218 shares of the biopharmaceutical company’s stock worth $156,000 after purchasing an additional 9,729 shares during the last quarter. Finally, Sanctuary Advisors LLC purchased a new position in shares of Amicus Therapeutics during the second quarter worth about $138,000.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.